LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Full Year of Fiscal 2021
July 29, 2021 at 04:05 pm EDT
Share
LeMaitre Vascular, Inc. provided earnings guidance for the third quarter, fourth quarter and full year of fiscal 2021. For the third quarter, the company expects operating income to be in the range of $9.3 million to $10.6 million, earnings per share to be in the range of $0.30 to $0.35 and sales to be in the range of $38.3 million to $40.3 million.
For the fourth quarter, the company expects operating income to be in the range of $9.3 million to $10.7 million, earnings per share to be in the range of $0.33 to $0.38 and sales to be in the range of $39.3 million to $41.3 million.
For the Full Year of Fiscal 2021, the company expects operating income to be in the range of $37.7 million to $40.4 million, earnings per share to be in the range of $1.30 to $1.40 and sales to be in the range of $154.1 million to $158.1 million.
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
LEMAITRE VASCULAR, INC. 
